Fig. 6: Therapeutic ferroptosis inhibition attenuates steatosis and features of metabolic syndrome in HFHFD. | Cell Death & Differentiation

Fig. 6: Therapeutic ferroptosis inhibition attenuates steatosis and features of metabolic syndrome in HFHFD.

From: Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease

Fig. 6

A Experimental design of therapeutic administration of UAMC-3203 or 0.9% NaCl (vehicle) via subcutaneous osmotic minipumps in animals fed high-fat high-fructose diet (HFHFD) or SD for 24 weeks. B Relative weight change during pharmacologic treatment. Area under curve (AUC) for intraperitoneal glucose tolerance test, adjusted for AUC before pharmacological intervention. Gonadal adipose tissue-on-bodyweight ratio. C Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol. D H&E and Masson’s trichrome. Magnification 100×, scale bar 200 µm. E Scoring of steatosis, lobular inflammation and NAFLD activity score. F Quantification of liver area enveloped by macrovesicular steatosis. Data from two independent experiments combined (n = 9). *p < 0.05; **p < 0.01; ***p < 0.001; #p < 0.05 for factor diet; §p < 0.05 for factor intervention. Analysis of covariance (ANOVA) with adjustment for relative weight change during pharmacologic intervention with post-hoc test if appropriate. Kruskal–Wallis with post-hoc testing for ordinal histologic scoring.

Back to article page